Table 3.
Reasons for Stopping Anti-IL-5Rα Therapy in 10 Patients. Multiple Answers per Patient Were Possible
| Reasons for Stopping Anti-IL-5Rα Therapy | n (% of All 60 Patients) |
|---|---|
| Inadequate treatment response | 4 (7) |
| Loss of Effectiveness (long term therapy or too long intervals) | 2 (3) |
| No effect on nasal polyps | 1 (2) |
| Adverse effects – total | 3 (5) |
| Weight loss | 1 (2) |
| Coronary artery spasm during therapy with benralizumab and sumatriptan | 1 (2) |
| Recurrence of chronic urticaria | 1 (2) |